Search results
Moderna says new-generation COVID vaccine more effective than Spikevax in adults 18 and over
Morningstar· 6 days agoModerna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 6 days agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks· 3 days agoCOVID-19 vaccine for the upcoming fall season. Subject to necessary permissions from the FDA and CDC, Novavax intends to market this ...
Column: This GOP-leaning political polling firm has turned into a purveyor of anti-vaccine...
LA Times via Yahoo News· 17 hours agoFor its May 2024 poll of 1,250 American adults, for instance, it asked, "Do you know someone...
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 4 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
Moderna Just Gave Investors Another Reason to Buy the Stock
Motley Fool via Yahoo Finance· 4 days agoModerna recently released results from a phase 3 study for its combo coronavirus/flu vaccine. This...
Gateway - Quartz
Quartz· 22 hours agoModerna said Tuesday that its updated COVID-19 vaccine demonstrated a stronger immune response than its current jab ...
Gateway - Quartz
Quartz· 1 day agoModerna stock jumped 7% during premarket trading on Thursday after the pharma company, known for its mRNA COVID-19 vaccine< ...
FDA Tells Vaccine Makers to Target New COVID Variant for Fall
WFMZ Eastern Pennsylvania and Western New Jersey· 6 days agoS. Food and Drug Administration announced Thursday. It's a turnaround for the agency: The new...
FDA asks COVID vaccine makers to target KP.2 strain, if feasible, for next shot
Reuters via AOL· 5 days agoThe Food and Drug Administration's change in recommendation, in an update dated Thursday, comes even...
